Market Cap
$1.1B
REPL
Replimune Group, Inc.
$13.04 ▼ -3.05%
Prev close $13.45Market cap$1.1B
ConsensusStrong Buy
12-mo target$19.50 (+49.2%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (5 insiders)High Impact Filing (7/10)28 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on REPL right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$801.6M
Inst. Activity
28 buys / 17 sells
Insider Activity
$33.0M buy / $1.7M sell
Insider Net $
$31.3M
Social Sentiment
58° Warm
SEC Reports
15
Press Releases
5
Price chart 30d -18.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Aug 21, 2026 Press Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help
Robbins LLP has announced a securities class action lawsuit against Replimune Group (REPL), alleging the company misled
Impact 7/10
Aug 20, 2026 Insider
Aug 19, 2026 SEC Astley-Sparke Philip gifted 50,000 shares
Director
Replimune insiders show a mixed cluster: Baker Bros. (10% owner) bought $1.52M in the public offering at $12.06, while t
CLUSTER — Impact 6/10
Aug 17, 2026 Insider
Aug 14, 2026 SEC Hill Emily Luisa sold 9,256 shares
Chief Financial Officer @ $14.28 ($132.2K)
Replimune reported fiscal Q1 2027 results with an in-line net loss of $69.8M ($-0.72 EPS), but the headline is the FDA a
8-K — Impact 7/10
Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is the FDA accelerated
PRESS-RELEASE — Impact 7/10
Aug 11, 2026 Insider
BAKER BROS. ADVISORS LP bought 126,394 shares
Director @ $12.06 ($1.5M)
Analyst ratings buy % +8.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 26, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 7, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 7, 2026 | Wedbush | UPGRADE | Outperform | 57% |
| Aug 4, 2026 | Leerink Partners | UPGRADE | Outperform | 49% |
| Jul 31, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Jul 31, 2026 | Cantor Fitzgerald | UPGRADE | Overweight | 49% |
| Jun 30, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Jun 26, 2026 | JP Morgan | UPGRADE | Overweight | 55% |
| Jun 1, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| May 29, 2026 | JP Morgan | UPGRADE | Neutral | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 7 | 1 | 1 | 0 | 86% | |
| Aug 1, 2026 | 4 | 7 | 2 | 1 | 0 | 79% | |
| Jul 1, 2026 | 3 | 5 | 5 | 1 | 0 | 57% | |
| Jun 1, 2026 | 1 | 0 | 7 | 3 | 2 | 8% | |
| May 1, 2026 | 1 | 0 | 6 | 4 | 2 | 8% | |
| Apr 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| Mar 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% |
Price targets
Where 6 covering analysts think REPL trades over the next 12 months.
$19.50 +49.2% upside Strong Buy
Current$13.07 Low$14.00 Median$19.50 High$24.00 6 analysts
$14.00$24.00
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment mood +20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
58°
Warm
BearishNeutralBullish
Recent posts
5 of the 6 biotech names I posted 5 weeks ago hit their catalyst (and the 1 that hasn't)
▲ 1 · 💬 1· ⚡ 0.5
Upcoming penny stock catalysts for June/July 2026 in Biotech and Pharma
▲ 1 · 💬 1· ⚡ 0.5
14 APRIL 2026 , WHAT ARE THE BIGGEST LOSERS PRE-MARKET AND WHY ?
▲ 1 · 💬 1· ⚡ 0.5
13 APRIL 2026 , WHAT ARE THE BIGGEST LOSERS PRE-MARKET AND WHY ?
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
15 SEC filing reports analyzed · 8 bullish, 4 bearish, 2 mixed, 1 neutral · avg impact 6.4/10.Plus 5 press releases.
MIXEDCLUSTER6/10
Replimune insiders show a mixed cluster: Baker Bros. (10% owner) bought $1.52M in the public offerin
Aug 19, 2026
BULLISH8-K7/10
Replimune reported fiscal Q1 2027 results with an in-line net loss of $69.8M ($-0.72 EPS), but the h
Aug 14, 2026
BULLISHPRESS-RELEASE7/10
Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is
Aug 14, 2026
MIXEDCLUSTER6/10
Replimune insiders (CEO, CFO, CMO, CAO) sold $906K in open-market sales on August 10, 2026, the same
Aug 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now
Oct 1, 2026
short_volume
Short Volume: REPL — 59.1% short (0.5M / 0.8M)
Short: 488,486 | Exempt: 1,617 | TRF Vol: 826,002 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: REPL — 62.4% short (0.9M / 1.5M)
Short: 929,470 | Exempt: 104 | TRF Vol: 1,489,524 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: REPL — 65.6% short (0.4M / 0.5M)
Short: 352,977 | Exempt: 764 | TRF Vol: 537,782 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: REPL — 75.1% short (0.7M / 0.9M)
Short: 660,656 | Exempt: 6,011 | TRF Vol: 879,701 | Short Ratio: 75.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.79 | $-0.82–$-0.76 | 12.5% | +5.4% | — | $0.0B | 2 |
| Next Q | $-0.76 | $-0.83–$-0.69 | 1.3% | +3.8% | — | $0.0B | 2 |
| Current FY | $-3.01 | $-3.21–$-2.80 | 11.1% | -1.0% | — | $0.0B | 2 |
| Next FY | $-1.82 | $-2.48–$-1.38 | 39.5% | +10.8% | 0↑ 1↓ | $0.2B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.788 | — |
| 7d ago | $-0.833 | +0.045 |
| 30d ago | $-0.833 | +0.045 |
| 60d ago | $-0.555 | -0.233 |
| 90d ago | $-0.535 | -0.253 |
Institutional ownership
Which big funds own REPL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $801.6M total value (72,389,862 shares) as of 2026-Q2. Top holders: BAKER, BlackRock,, RTW. Net buying activity: 28 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 11,045,336 | $122.3M | 15.3% | — |
| BlackRock, Inc. | 8,958,535 | $99.2M | 12.4% | ADD +43.6% |
| RTW INVESTMENTS, LP | 7,411,581 | $82.0M | 10.2% | — |
| GOLDMAN SACHS GROUP INC | 4,541,018 | $50.3M | 6.3% | ADD +99.4% |
| STATE STREET CORP | 4,440,144 | $49.2M | 6.1% | — |
| Caption Management, LLC | 2,952,800 | $32.7M | 4.1% | ADD +73.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,896,004 | $32.1M | 4.0% | — |
| AQR CAPITAL MANAGEMENT LLC | 2,566,241 | $28.4M | 3.5% | — |
| JANE STREET GROUP, LLC | 2,322,545 | $25.7M | 3.2% | DOUBLED +442.5% |
| Erste Asset Management GmbH | 2,120,000 | $23.7M | 3.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 6,239,239 | 8,958,535 | +43.6% | $99.2M |
| GOLDMAN SACHS GROUP INC | ADD | 2,277,276 | 4,541,018 | +99.4% | $50.3M |
| JANE STREET GROUP, LLC | DOUBLED | 428,145 | 2,322,545 | +442.5% | $25.7M |
| UBS Group AG | ADD | 581,210 | 1,128,276 | +94.1% | $12.5M |
| Artisan Partners Limited Partnership | NEW | — | 973,496 | — | $10.8M |
| FMR LLC | TRIM | 2,045,490 | 929,375 | -54.6% | $10.3M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 300,833 | 821,958 | +173.2% | $9.1M |
| CITADEL ADVISORS LLC | ADD | 398,729 | 784,233 | +96.7% | $8.7M |
| Caption Management, LLC | ADD | 451,822 | 783,873 | +73.5% | $8.7M |
| Nuveen, LLC | DOUBLED | 57,614 | 677,524 | +1076.0% | $7.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 37 transactions. Net $31.3M — $33.0M bought, $1.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Astley-Sparke Philip | Director | GIFT | 50,000 | — | — |
| Aug 17, 2026 | Hill Emily Luisa | Chief Financial Officer | SELL | 9,256 | $14.28 | $132.2K |
| Aug 11, 2026 | BAKER BROS. ADVISORS LP | Director | BUY | 126,394 | $12.06 | $1.5M |
| Aug 11, 2026 | BAKER BROS. ADVISORS LP | Director | BUY | 2,609,946 | $12.06 | $31.5M |
| Aug 10, 2026 | Xynos Konstantinos | Chief Medical Officer | SELL | 11,447 | $12.97 | $148.5K |
| Aug 10, 2026 | Hill Emily Luisa | Chief Financial Officer | SELL | 11,448 | $12.97 | $148.5K |
| Aug 10, 2026 | Schwendenman Andrew | Chief Accounting Officer | SELL | 7,632 | $12.97 | $99.0K |
| Aug 10, 2026 | Patel Sushil | Chief Executive Officer | SELL | 39,341 | $12.97 | $510.3K |
| Jun 1, 2026 | Sarchi Christopher | Chief Commercial Officer | SELL | 12,000 | $9.24 | $110.9K |
| May 18, 2026 | Hill Emily Luisa | Chief Financial Officer | SELL | 7,812 | $5.08 | $39.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for REPL.
Shares short
22,754,597
Settlement Sep 15, 2026
Change vs prior
-3.3%
Semi-monthly cycle
Days to cover
11.1
At avg daily volume
Of shares outstanding
≈24.1%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Jul 30, 2026 | T2 | News Released | Not resumed |
| Jul 30, 2026 | T3 | Resumption Scheduled | Resumed |
| Jul 30, 2026 | T1 | News Pending | Not resumed |
All REPL filing & press-release reports (20)
- PRESS-RELEASE reportAug 21, 2026
- CLUSTER reportAug 19, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 12, 2026
- 424B5 reportAug 10, 2026
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportAug 7, 2026
- 8-K reportJul 30, 2026
- S-3/A reportJul 24, 2026
- 8-K reportJun 29, 2026
- PRESS-RELEASE reportJun 29, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportMay 31, 2026
- PRESS-RELEASE reportMay 30, 2026
- 8-K reportMay 29, 2026
- PRESS-RELEASE reportMay 29, 2026
- CLUSTER reportMay 20, 2026